These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11298482)

  • 21. Study of plasma level of atorvastatin and its effect on lipid profile.
    Valera HR; Ganguly B
    Indian J Physiol Pharmacol; 2009; 53(1):73-82. PubMed ID: 19810580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography.
    Hinoi T; Matsuo S; Tadehara F; Tsujiyama S; Yamakido M
    Am J Cardiol; 2005 Jul; 96(1):89-91. PubMed ID: 15979441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials.
    Takagi H; Umemoto T
    Int J Cardiol; 2012 Jan; 154(2):183-6. PubMed ID: 21996415
    [No Abstract]   [Full Text] [Related]  

  • 24. Atorvastatin and portal pressure.
    Zamora-Valdés D; Uribe M; Méndez-Sánchez N
    Hepatology; 2007 Oct; 46(4):1309-10; author reply 1310. PubMed ID: 17894304
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of atorvastatin on plasma fibrinogen.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    Lancet; 1998 Feb; 351(9102):569-70. PubMed ID: 9492781
    [No Abstract]   [Full Text] [Related]  

  • 26. Atorvastatin and low-density lipoprotein subfractions profile in mixed hyperlipidaemia: a contributory effect of reduced hepatic lipase activity?
    Heller F; Descamps O; Hondekijn JC; Desager JP
    Ann Clin Biochem; 1999 Nov; 36 ( Pt 6)():788-9. PubMed ID: 10586326
    [No Abstract]   [Full Text] [Related]  

  • 27. Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin.
    Chen YX; Wang XQ; Fu Y; Yao YJ; Kong MY; Nie RQ; Wang JF
    Int J Cardiol; 2011 Jan; 146(2):140-4. PubMed ID: 19570586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients.
    Goulas A; Kosmidou M; Hatzitolios AI; Molyva D; Fidani L; Giannopoulos S; Mirtsou V
    Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):559-62. PubMed ID: 18331394
    [No Abstract]   [Full Text] [Related]  

  • 29. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
    Matafome P; Louro T; Rodrigues L; Crisóstomo J; Nunes E; Amaral C; Monteiro P; Cipriano A; Seiça R
    Diabetes Metab Res Rev; 2011 Jan; 27(1):54-62. PubMed ID: 21218508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated lipoprotein(a) with statin therapy.
    Spielberg T
    Am J Cardiol; 2000 May; 85(9):1162. PubMed ID: 10896622
    [No Abstract]   [Full Text] [Related]  

  • 31. Atorvastatin and glatiramer acetate: new hope in MS?
    Bradbury J
    Lancet Neurol; 2006 May; 5(5):386-7. PubMed ID: 16639832
    [No Abstract]   [Full Text] [Related]  

  • 32. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
    Ercan E; Tengiz I; Altuglu I; Sekuri C; Aliyev E; Ercan HE; Akin M
    Kardiol Pol; 2004 May; 60(5):454-8. PubMed ID: 15247960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
    Makkena B; Salti H; Subramaniam M; Thennapan S; Bonow RH; Caira F; Bonow RO; Spelsberg TC; Rajamannan NM
    J Am Coll Cardiol; 2005 Feb; 45(4):631-3. PubMed ID: 15708716
    [No Abstract]   [Full Text] [Related]  

  • 35. Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients.
    Silverstein DM
    Pediatr Transplant; 2003 Feb; 7(1):7-10. PubMed ID: 12581321
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Religious attendance: more cost-effective than lipitor?
    Denberg T
    J Am Board Fam Med; 2006; 19(4):430; author reply 431-3. PubMed ID: 16809663
    [No Abstract]   [Full Text] [Related]  

  • 38. Atorvastatin in the management of an index patient with complete hepatic lipase deficiency.
    Hegele RA; Little JA; Connelly PW
    Atherosclerosis; 1999 Mar; 143(1):219-22. PubMed ID: 10208500
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
    Samoĭlenko EIu; Naumov VG; Tvorogova MG; Ezhov MV; Sergienko IV; Kukharchuk VV
    Kardiologiia; 2007; 47(2):4-8. PubMed ID: 17495815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
    Karpisek M; Stejskal D; Kotolova H; Kollar P; Janoutova G; Ochmanova R; Cizek L; Horakova D; Yahia RB; Lichnovska R; Janout V
    Eur J Clin Invest; 2007 Aug; 37(8):637-42. PubMed ID: 17635574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.